Analyst Upgrades: Tesla Motors, Monsanto, AbbVie

Analysts upwardly revised their ratings and price targets on Tesla Motors Inc (NASDAQ:TSLA), Monsanto Company (NYSE:MON), and AbbVie Inc (NYSE:ABBV)

Jun 8, 2015 at 10:01 AM
facebook twitter linkedin


Analysts are weighing in today on electric automaker Tesla Motors Inc (NASDAQ:TSLA), agricultural concern Monsanto Company (NYSE:MON), and biopharmaceutical firm AbbVie Inc (NYSE:ABBV). Here's a quick roundup of today's bullish brokerage notes on TSLA, MON, and ABBV.

  • TSLA is up 2.6% this morning at $255.70 on reports Panasonic is sending hundreds of employees to the car producer's Gigafactory in Nevada to prepare to make lithium-ion batteries next year. On top of this, Baird raised its price target to $335 from $275, marking a 31% premium to current levels. The shares have been solid on the charts, adding 15% in 2015. Option traders have been betting on more upside, too. Tesla Motors Inc's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 1.35 is higher than three-fourths of comparable readings from the past year. On a separate note, TSLA will hold its annual shareholder meeting tomorrow.

  • MON's second takeover bid for Syngenta AG (ADR) (NYSE:SYT) has been rejected, with the latter company citing regulatory concerns. Regardless, Monsanto Company is up 0.6% on the day at $114.62, as it received an upgrade at Atlantic Equities to "neutral" from "underweight." Analysts are split on the stock. While seven brokerage firms say it's a "strong buy," six others deem it only a "hold." Going by its recent price action, the bearish attention seems more deserving. MON has dropped 9% since touching a 2015 high of $126 on Feb. 25.

  • Thanks to a pair of price-target hikes, ABBV has added 0.6% this morning to hit $67.90. Specifically, Jefferies upped its price target to $90 from $86, while Credit Suisse raised its mark to $72 from $69. The Street already has a decidedly bullish stance on the shares, with 80% of brokerage firms calling them a "strong buy," and not a single "sell" to be found. On the charts, AbbVie Inc has been gaining lately, outpacing the S&P 500 Index (SPX) by almost 15 percentage points over the past three months. 
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners